Brolucizumab stabilizes retinal exudation and fluid, improving visual outcomes in wet AMD management. Study showed BCVA and CRT improvements at 6 and 12 months, with minimal adverse events. Small ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the ...

Age-related macular degeneration (AMD) is a leading cause of vision loss among people aged 50 and older. While treatments for the wet form of AMD have shown promise, the dry form, which accounts for ...

AMD primarily affects central vision, complicating activities like reading and driving, but does not cause complete blindness. Wet AMD involves abnormal blood vessel growth, while dry AMD progresses ...

The last time I spoke about REGENXBIO (RGNX), it was with respect to a Seeking Alpha article entitled "Regenxbio: With Additional MPS II Data, Program Advancement Remains On Track". With respect to ...

Age-related macular degeneration (AMD), classified into dry and wet types, poses a significant threat to the vision of the elderly population globally. Despite its prevalence, the exact molecular ...

PulseSight Therapeutics completes patient enrolment in phase I trial of PST-611 to treat dry AMD/geographic atrophy: Paris, France Friday, January 23, 2026, 18:00 Hrs [IST] PulseS ...

Age-related macular degeneration (AMD) once meant a slow, irreversible loss of vision, and many people still believe that's ...

While dry AMD, in most instances, does not culminate in total blindness (as peripheral vision is usually retained), the significant and irreversible loss of central vision can severely impair a person ...